This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2024 Zacks Investment Research | 10 S Riverside Plaza Suite #1600 | Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +24.10% per year. These returns cover a period from January 1, 1988 through October 7, 2024. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Steris (STE) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Steris (STE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Here's Why You Should Invest in STERIS (STE) Stock Right Now
by Zacks Equity Research
With the acquisition of U.K.-based outsourced sterilization services provider Synergy Health, STERIS (STE) has become the global leader in infection prevention and sterilization.
STERIS Rides on Favorable Industry Trends, Rivalry a Concern
by Zacks Equity Research
STERIS (STE) is currently displaying strong top-line growth on encouraging market trends along with a new product and service portfolio.
STERIS (STE) Dips on New Restructuring Plan, Layoff Decision
by Zacks Equity Research
STERIS (STE) aims to stop the production of the worst-hit products and move toward the existing manufacturing operations by fiscal 2020.
Why Is Steris (STE) Down 0.6% Since Last Earnings Report?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Steris (STE) Hits Fresh High: Is There Still Room to Run?
by Zacks Equity Research
Steris (STE) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
STERIS (STE) Q2 Earnings & Revenues Beat Estimates, Rise Y/Y
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q2.
Steris (STE) Q2 Earnings and Revenues Surpass Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 1.85% and 3.35%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
Will Steris (STE) Beat Estimates Again in Its Next Earnings Report?
by Zacks Equity Research
Steris (STE) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Steris (STE) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Steris (STE) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
STERIS (STE) Strategic Growth Strong Amid Several Headwinds
by Zacks Equity Research
STERIS (STE) impresses with favorable underlying market trends apart from new products and service offerings. Yet, a severe competition lurking beneath is worrisome for the company.
Why Is Steris (STE) Down 1.2% Since Last Earnings Report?
by Zacks Equity Research
Steris (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
STERIS (STE) Strategic Growth Strong, Competition a Woe
by Zacks Equity Research
STERIS' (STE) beneficial underlying market trends along with new product and service offerings are impressive. Meanwhile, the company worries over facing a severe competition.
STERIS (STE) Q1 Earnings & Revenues Beat Estimates, Up Y/Y
by Zacks Equity Research
STERIS (STE) continues to gain from strength in all business segments in Q1.
Steris (STE) Q1 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Steris (STE) delivered earnings and revenue surprises of 2.04% and 0.01%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
Can Solid European Sales Boost Inogen (INGN) in Q2 Earnings?
by Zacks Equity Research
Strong performance in Europe is likely to boost Inogen's (INGN) top line in Q2. However, decline rental-revenues is a concern.
Intuitive Surgical's FDA Approval for SureForm to Aid Surgery
by Zacks Equity Research
Intuitive Surgical's (ISRG) SureForm 60 stapler receives FDA approval; strengthens its profile for minimally invasive surgical solutions.
MASI or STE: Which Is a Better Investment Option Right Now?
by Zacks Equity Research
Masimo's (MASI) and STERIS' (STE) strong expected growth rates and impressive price performance make them close contenders in the Medical Instruments space.
Here's Why You Must Add STERIS (STE) to Your Portfolio Now
by Zacks Equity Research
STERIS' (STE) acquisition of U.K.-based outsourced sterilization services provider, Synergy Health plc, remains one of its key strategic moves.
Medical Device Firms in Focus on Expanded R&D Scope: 5 Picks
by Zacks Equity Research
The suspension of the Medical Device Tax, the evolution of mechatronics and big data in the MedTech space make some of the stocks lucrative picks for investment.
Mechatronics for Healthcare: 3 MedTech Stocks to Bet On
by Nabaparna Bhattacharya
Here we analyze how Medical Mechatronics is creating new opportunities in MedTech for investors who are keen on putting their money in the healthcare space for longer-term gains.
Medical Device Industry Outlook - June 2018
by Zacks Equity Research
The medical device industry's global annual sales is forecast to rise more than 5% a year to reach nearly $800 billion by 2030.
Why Is STERIS (STE) Up 5.2% Since Its Last Earnings Report?
by Zacks Equity Research
STERIS (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is STERIS (STE) Up 7.7% Since Its Last Earnings Report?
by Zacks Equity Research
STERIS (STE) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Should You Buy STERIS (STE) Ahead of Earnings?
by Zacks Equity Research
STERIS (STE) is seeing favorable earnings estimate revision activity as of late, which is generally a precursor to an earnings beat.